Modalis Therapeutics Corporation Logo

Modalis Therapeutics Corporation

Develops genetic medicines using a proprietary epigenome editing technology.

4883 | T

Overview

Corporate Details

ISIN(s):
JP3922600006
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号

Description

Modalis Therapeutics Corporation is a biotechnology company developing precision genetic medicines for serious disorders. The company's core technology is CRISPR-GNDM®, a proprietary epigenome editing platform. This technology regulates the expression of specific genes—selectively activating or suppressing them—without altering the underlying DNA sequence or causing double-strand breaks. CRISPR-GNDM® utilizes a compact epigenome editor designed for efficient delivery to target cells using adeno-associated virus (AAV) vectors. The company advances its programs through a hybrid model of in-house development and collaborative partnerships, with a pipeline focused on therapeutic areas such as muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:48
訂正有価証券届出書(組込方式)
Japanese 237.5 KB
2025-08-14 08:31
確認書
Japanese 8.9 KB
2025-08-14 08:30
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 266.6 KB
2025-08-07 08:32
有価証券届出書(組込方式)
Japanese 334.6 KB
2025-03-28 07:52
臨時報告書
Japanese 28.4 KB
2025-03-27 08:32
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 24.1 KB
2025-03-27 08:30
確認書
Japanese 8.7 KB
2025-03-27 08:29
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-21 07:31
臨時報告書
Japanese 21.5 KB
2024-08-13 08:14
訂正有価証券届出書(組込方式)
Japanese 293.9 KB
2024-08-13 07:58
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 249.6 KB
2024-08-13 07:58
確認書
Japanese 8.9 KB
2024-08-07 08:01
有価証券届出書(組込方式)
Japanese 495.2 KB
2024-05-14 06:00
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 166.1 KB
2024-05-14 06:00
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all Modalis Therapeutics Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Modalis Therapeutics Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Modalis Therapeutics Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.